St. Teresa Medical, Inc. today announced the enrollment of the first patient into its human clinical trial for its product, SURGICLOT®, which is classified by the U.K.’s regulatory agency MHRA, and Nemko PreSafe, a global testing and certification company specializing in medical devices, as a medical device class 111 with medicinal ancillary action. On June 18, St. Teresa Medical received approval for a 40-patient study from MHRA in the U.K.
According to CEO and Co- Founder Philip Messina, on July 6 Mr. Sanjeev Madan, a consultant orthopedic surgeon at Doncaster & Bassetlaw Hospital in South Yorkshire, U.K., performed a pelvic osteotomy (bone is shortened, lengthened, or alignment is changed) using the SURGICLOT® dressing on the first patient in St. Teresa’s human trial. Dr. Tim Floyd, chief scientific officer for St. Teresa Medical, was present at the first surgery.
“It was Mr. Madan’s impression, as well as mine, that the reduction in blood loss was significant and dramatic, and that its use will lead to less morbidity for patients, shorter surgical times, lower costs, fewer transfusions, and less time in hospital,” said Floyd.
SURGICLOT® may reduce length of hospital stays
“Mr. Madan was very pleased with the results, and commented it will allow him to send patients home sooner because of vastly reduced blood loss. The SURGICLOT® dressing is the only hemostatic dressing available with both dissolvable and resorbable qualities. The dressing dissolves in seconds to minutes, and leaves behind a robust clot to obtain hemostasis in less than three minutes,” Messina added.
The dressing achieves its primary mode of action through the solid electrospun dextran, which initially creates a physical barrier to oozing, flowing or pulsatile bleeding. The SURGICLOT® dressing will be the first hemostatic dressing indicated for use in cancellous bone bleeding when the dressing is CE Marked (a European Union safety requirement) after the human trial is completed during the Fall of 2015.
St. Teresa Medical’s Good Laboratory Practice animal studies required by both the MHRA and the U.S. FDA have scientifically proven the U.S. pharmacopeia-grade electrospun dextran, human thrombin and fibrinogen are completely resorbed by the tissue.
About St. Teresa
St. Teresa Medical, Inc.®, based in St. Paul, Minn., is a medical-device company developing a new unique dissolvable hemostatic dressing called SURGICLOT®. Dressings currently used for surgery or severe trauma have limited clotting capabilities, and many have a foreign body delivery carrier that can cause unwanted side effects, including swelling and inflammation. The patent-pending SURGICLOT technology accelerates clotting by adding clot-forming proteins to the bleeding site, creating a quick robust clot, potentially saving lives. The product is the only hemostatic dressing with a rapidly dissolvable and absorbable electrospun dextran barrier (no collagen or cellulose). SURGICLOT, once approved with CE Marking in Europe, will be the only hemostatic agent that has the indication for use in all cancellous bone bleeding. SURGICLOT will fill an unmet need in the rapidly growing orthopedic market. The original technology for SURGICLOT was exclusively transferred to St. Teresa Medical from Virginia Commonwealth University and the Henry M. Jackson Foundation for the Advancement of Military Medicine. For more information, see www.StTeresaMedical.com.
Help employers find you! Check out all the jobs and post your resume.
